Adagene's Upcoming Investor Conferences in September
Adagene Inc., a pioneering company in antibody-based therapies, recently announced its involvement in two significant investor conferences in September. The company is excited to showcase its strategic vision and innovations. Chief Strategy Officer Mickael Chane-Du will be participating in one-on-one meetings and delivering a presentation during a fireside chat.
H.C. Wainwright 27th Annual Global Investment Conference
The first event is the H.C. Wainwright Annual Global Investment Conference, set to occur on September 8. This prestigious conference will take place at the Lotte New York Palace Hotel. During the conference, Mickael Chane-Du will discuss Adagene’s mission and the cutting-edge technologies that are redefining the landscape of cancer treatment.
Morgan Stanley 23rd Annual Global Healthcare Conference
Following swiftly, on September 10, Adagene will also participate in the Morgan Stanley Global Healthcare Conference at the Sheraton New York Times Square Hotel. Mickael is slated to engage with investors and share insights about the company’s latest advancements and strategic direction.
Webcast Availability
For those unable to attend the events in person, Adagene will make webcasts of the presentations available online. Investors and stakeholders can find these valuable updates on the company’s official website under the investors section. These webcasts will be accessible for at least 30 days, ensuring that the insights shared reach a broad audience.
Innovative Technologies at the Core of Adagene
Adagene Inc., trading under Nasdaq: ADAG, stands at the forefront of biopharmaceutical innovation. The company is deeply committed to improving the discovery and development of advanced therapies for cancer treatment. Through a unique integration of computational biology and artificial intelligence, Adagene is designing novel antibodies tailored to address the specific needs of patients worldwide.
The company is particularly known for its SAFEbody precision masking technology, which enhances the therapeutic efficacy of antibodies while minimizing potential side effects. This technology represents a significant leap in the treatment of cancer and positions Adagene uniquely within the oncology space.
Pioneering Pipeline and Clinical Programs
Adagene’s dynamic pipeline is distinguished by several promising therapy programs. One standout is their lead clinical candidate, ADG126 (muzastotug). This innovative therapy targets CTLA-4, aiming to combat cancer more effectively by specifically zeroing in on regulatory T cells in the tumor microenvironment. Current research highlights the potential of this approach, particularly in treating Metastatic Microsatellite-stable Colorectal Cancer.
Collaborative Opportunities and Future Directions
The transformative nature of Adagene's technologies has garnered attention from prestigious collaborators in the biopharmaceutical space. These partnerships are pivotal in leveraging Adagene’s precision masking technology across various therapeutic modalities, ushering in new possibilities for improved patient outcomes and novel treatment pathways.
Get in Touch with Adagene
For more detailed insights into their innovative strategies and ongoing clinical trials, interested parties are encouraged to reach out or visit the Adagene website. The company actively engages with its investor community and provides updates on significant developments through various channels.
Investor Contacts
For inquiries, please reach out to:
Raymond Tam
Email: raymond_tam@adagene.com
Corey Davis
LifeSci Advisors
Email: cdavis@lifesciadvisors.com
Frequently Asked Questions
What are the key dates for Adagene's investor conferences?
The investor conferences occur on September 8 and September 10, with presentations by CSO Mickael Chane-Du.
Where can I access the webcasts of these conferences?
The webcasts will be available in the investors section of Adagene’s website for at least 30 days following each event.
What innovative technology does Adagene focus on?
Adagene specializes in antibody-based therapies, particularly through their SAFEbody precision masking technology.
What is the main focus of Adagene's lead clinical program?
The lead program, ADG126, targets CTLA-4 to effectively treat cancer by focusing on regulatory T cells.
How can investors get in touch with Adagene?
Investors can reach out via the emails provided for Raymond Tam and Corey Davis for inquiries.
